Department of Urology, University of California, Irvine.
The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD.
Urol Oncol. 2021 Oct;39(10):735.e17-735.e23. doi: 10.1016/j.urolonc.2021.05.024. Epub 2021 Aug 4.
The role of renal biopsy prior to surgical intervention for a renal mass remains controversial despite the fact that for all other urological organs except the testicle, biopsy inevitably precedes treatment as is true for all other specialties dealing with solid masses (e.g. thyroid, breast, colon, liver, etc.). Accordingly, we sought to determine the impact of a routine biopsy regimen on the course of patients with cT1a lesions in comparison with a contemporary series of cT1a individuals who went directly to treatment without a preoperative biopsy.
We analyzed a multi-institutional, prospectively maintained database of patients who underwent an office-based, ultrasound-guided, renal mass biopsy (RMB) for a cT1a renal mass (i.e. ≤4cm in largest dimension). Controls were selected from all patients in the database who had a cT1a renal lesion but did not undergo RMB. Both groups were analyzed for differences in treatment modality and surgical pathology results.
A total of 72 RMB and 73 control patients were analyzed. The groups were similar in regards to their baseline characteristics. Overall RMB diagnostic rate was 75%. Surgical pathology revealed that excision of benign tumors was eight-fold less in the RMB cohort compared to the control group (3% vs. 23%; P < 0.001). Additionally, the rate of active surveillance in the RMB cohort was nearly three times higher at 35% vs. 14% for the controls (P < 0.001). Biopsy was concordant with surgical pathology in 97% of cases for primary histology (i.e. benign vs. malignant), 97% for histologic subtype, and 46% for low (I or II) vs. high (III or IV) grade. On multivariate analysis patients who underwent surgical intervention without preoperative RMB were 6.7 times more likely to have benign histopathology compared to patients who underwent preoperative RMB (OR 6.7, 95% CI = 0.714 - 63.626, P = 0.096). There were no procedural or post-procedural RMB complications.
For patients with cT1a lesions, the implementation of routine office-based RMB led to a significant decrease in the rate of surgical intervention for benign tumors. This practice also resulted in a higher rate of active surveillance for the management of renal cortical neoplasms with benign histopathology compared to a control group.
尽管对于除睾丸以外的所有泌尿外科器官,活检在治疗前都是不可避免的,这与所有处理实体瘤的其他专业(如甲状腺、乳腺、结肠、肝脏等)相同,但在对肾脏肿块进行手术干预之前进行肾活检的作用仍然存在争议。因此,我们试图确定常规活检方案对 cT1a 病变患者病程的影响,并将其与直接进行治疗而未行术前活检的当代 cT1a 患者系列进行比较。
我们分析了一个多机构、前瞻性维护的数据库,该数据库包含了 72 例接受办公室超声引导肾肿块活检(RMB)的 cT1a 肾肿块(即最大直径≤4cm)患者。对照组是从数据库中所有患有 cT1a 肾病变但未行 RMB 的患者中选择的。比较两组患者在治疗方式和手术病理结果方面的差异。
共分析了 72 例 RMB 和 73 例对照组患者。两组患者的基线特征相似。总体 RMB 诊断率为 75%。手术病理显示,与对照组相比,RMB 组切除良性肿瘤的比例低 8 倍(3%对 23%;P<0.001)。此外,在 RMB 组中,主动监测的比例几乎是对照组的三倍,为 35%对 14%(P<0.001)。在原发性组织学(即良性 vs. 恶性)、组织学亚型和低(I 或 II)级 vs. 高(III 或 IV)级方面,活检与手术病理的一致性分别为 97%、97%和 46%。多变量分析显示,与术前接受 RMB 的患者相比,未行术前 RMB 而直接接受手术干预的患者良性组织学的可能性高 6.7 倍(OR 6.7,95%CI=0.714-63.626,P=0.096)。无操作或操作后 RMB 并发症。
对于 cT1a 病变患者,实施常规的办公室 RMB 显著降低了良性肿瘤手术干预的比例。与对照组相比,这一做法还导致具有良性组织学的肾皮质肿瘤的主动监测率更高。